Premarket Stock Movers — August 14, 2026: Why STKH, CAPR, AKAN, CYCU & SXTC Are Surging

STKH — Steakholder Foods Ltd. (+95.9%)

Steakholder Foods is surging nearly 96% in premarket trading on August 14, 2026, changing hands at $5.70 on volume of roughly 10.99 million shares — already above its 20-day average of 8.37 million before the opening bell. That kind of volume arrival ahead of the open signals strong directional interest, though premarket volume is typically thinner and more volatile than regular-session trading.

Why it's moving: No specific catalyst headline is on file for this morning's spike, and STKH's recent SEC filings — three routine 6-K foreign-event disclosures in late July and early August — are all rated neutral. With no clear fundamental driver, this move appears momentum- and technically-driven. Traders should be especially cautious: when a stock nearly doubles with no confirmed news, the move is often fragile and can reverse sharply once the regular session opens.

The short-squeeze angle (a squeeze occurs when heavily shorted stocks rise, forcing short sellers to buy shares to cover their losses, which accelerates the rally) offers little explanation here. STKH's squeeze score is just 8 out of 100, short interest is a minimal 72,731 shares, and days to cover — the number of days it would theoretically take short sellers to buy back all their shares at average daily volume — sits at just 1.7. A squeeze-driven pop is unlikely. The short-sale restriction (SSR) is active, meaning regulators have temporarily limited certain forms of short selling after yesterday's decline; that can create a mild mechanical tailwind but isn't a catalyst on its own.

On the prior-day chart, STKH printed a three inside down candlestick pattern — a bearish continuation signal that forms when a smaller candle is engulfed by the prior session's body, followed by a close below it. The RSI is 56 (neutral territory) and the ADX reading of 62 signals a strongly trending environment. The stock sits 54% below its 52-week high, and the MA stack is mixed. The conviction score is 53/100 with a grade of C. Given the absence of a confirmed catalyst, this is a name to watch, not chase — relative volume is elevated, but without a story behind it, gaps like this frequently fill. STKH has also appeared in prior StockSetups premarket scans; see the August 10 premarket recap for context.

CAPR — Capricor Therapeutics, Inc. (+87.9%)

Capricor Therapeutics is the morning's standout fundamental mover, jumping 88% to $7.95 on premarket volume of over 20.4 million shares — more than three times its 20-day average of 6.35 million. A surge of this magnitude on this volume in a healthcare name almost always means a binary catalyst, and that's exactly what's happening here.

Why it's moving: Multiple credible headlines confirm a pair of high-impact events hitting simultaneously. According to GuruFocus, CAPR stock is surging on an FDA application amendment, with the company actively in the regulatory countdown for a key submission. StocksToTrade and other outlets add that positive data published in The Lancet — one of the world's most prestigious medical journals — and a significant analyst upgrade are compounding the FDA-related momentum. These are exactly the kinds of binary binary catalysts that can reprice a small biotech overnight. An 8-K filed August 13 (earnings, neutral) and two Schedule 13G passive-stake filings in early August round out the recent SEC activity.

With a squeeze score of 73/100 and short interest of 15.58 million shares representing 10.8 days to cover, CAPR carries a meaningful short-squeeze setup on top of the news. A high "days to cover" means short sellers face a long road to unwind their positions at average volume — so a sharp news-driven rally can force panicked covering that amplifies the move well beyond what fundamentals alone would justify.

The prior-day chart carried a bearish MA stack and an RSI of just 26 — deeply oversold — with the stock sitting 88% below its 52-week high and carrying a grade of D and conviction of just 8/100. That washed-out technical setup, combined with heavy short interest, is the classic fuel for a violent short squeeze when a catalyst arrives. Reddit is picking up the name at rank #48 on r/all-stocks with 18 mentions, up from just 1 the prior day — early-stage retail awareness that could add further fuel during the regular session. That said, biotech binary events cut both ways, and stocks that surge 80–115% premarket on FDA-related news frequently give back a large portion of those gains once institutional traders reassess risk.

AKAN — Akanda Corp. (+55.7%)

Akanda Corp., a micro-cap healthcare name with a market cap of just $10 million, is surging 55.7% to $7.88 in premarket trading on volume of 6.45 million shares — an extraordinary 17.8× its 20-day average of just 362,254 shares. Relative volume (RVOL) this extreme in a micro-cap almost always signals a specific catalyst, though the nature of it requires careful reading.

Why it's moving: Investing.com is directly asking "Why is Akanda stock surging today?" in a headline, which suggests the catalyst may not be entirely self-evident. StocksToTrade is simultaneously flagging it as a "high-risk setup," and timothysykes.com notes traders are watching key support levels following a pullback. A 6-K foreign-event filing on August 13 is on file but rated neutral. The picture is mixed: there appears to be some catalyst drawing attention — possibly related to that foreign disclosure — but no definitive confirmed business news is available in the data. Treat the catalyst as unclear pending further information; this is a momentum-driven, ultra-low-float situation with all the hallmarks of a high-risk, high-volatility trade.

The squeeze score is just 2/100, and short interest is negligible at 6,244 shares, so this is emphatically not a squeeze situation. What drives moves like this in a $10M-market-cap stock with a 6,244-share short position is almost entirely order-flow momentum — a small number of buyers in a thinly traded name can move the price dramatically. Prior-day technicals show RSI at 30 (oversold), ADX of just 10 (weak trend), and a mixed MA stack, with the stock sitting 91.1% below its 52-week high. Conviction is 27/100, grade D. There is no margin of safety in the technical setup, and the risk of a sharp reversal — especially when headlines themselves note it's a "high-risk setup" — is very real.

CYCU — Cycurion, Inc. (+35.7%)

Cycurion, a micro-cap cybersecurity company, is trading up 35.7% to $0.95 premarket on volume of 21.03 million shares. Notably, that volume is actually below the 20-day average of 49.16 million — meaning while the move is large, the premarket activity is lighter than this stock's typical day, a reminder that price moves in thinly priced stocks can be outsized relative to volume.

Why it's moving: The catalyst is clear: Cycurion just reported Q2 results that beat consensus on both revenue and earnings per share, with gross margin improving nearly 5× year-over-year, and the company announced it has landed a $54.6 million contract, per Stock Titan and Yahoo Finance. For a company with a $7.5 million market cap, a $54.6 million contract is a transformational headline number and explains the sharp premarket gap-up.

One important counterweight: Cycurion has a Nasdaq delisting review underway, with a panel hearing scheduled for August 20. This is a material risk — if the company loses its Nasdaq listing, it would be forced to trade on the OTC markets, which typically reduces liquidity and institutional access dramatically. That hearing date is just six days away, which means traders holding through the week face binary listing-decision risk on top of normal price volatility. The company has also filed two bearish-flagged 8-Ks related to dilution in early August, which can weigh on existing shareholders. The conviction score is 22/100, grade D, and the MA stack is mixed — this is speculative territory on multiple fronts, regardless of the strong contract news.

SXTC — China SXT Pharmaceuticals, Inc. (+33.2%)

China SXT Pharmaceuticals is up 33.2% to $4.37 in premarket trading on 13.01 million shares — though that volume is well below the stock's 20-day average of 118 million shares, indicating this is a quieter-than-usual premarket session for a name that regularly sees heavy turnover.

Why it's moving: No specific catalyst headline is on file for today's move, and the most recent SEC filings are a July 24 424B5 (a follow-on share offering prospectus, which is bearish for existing shareholders as it signals dilution) and a neutral 6-K. The absence of a confirmed catalyst means this move looks technically or momentum-driven at this stage. Traders should note that follow-on offerings from late July can create lingering supply overhang, which tends to cap sustained rallies.

What SXTC does have going for it is the cleanest technical setup of the five stocks in this morning's scan. The prior-day chart shows a bullish MA stack (short-term moving averages above long-term ones, generally a sign of underlying upward momentum), RSI at 70 (strong but approaching overbought territory), and a Minervini trend-template score of 6 — the highest of today's group. The conviction score is 72/100 with a grade of B, and the stock is only 27.6% below its 52-week high — significantly less beaten-down than the other names here. With short interest of just 22,521 shares and a squeeze score of 15/100, this is not a squeeze play; it's a pure price-momentum move in a stock that already has technical strength behind it. That said, no news means no story — and moves without a story tend to be short-lived.

The bottom line

This morning's five biggest premarket movers span nearly the full spectrum of market dynamics: a potential FDA catalyst and Lancet data publication driving CAPR, a major contract announcement lifting CYCU, and mostly momentum-driven or unexplained surges in STKH, AKAN, and SXTC. Before the regular session opens, keep the following risks front of mind.

Premarket prices are not final prices. Liquidity is thin before 9:30 AM ET, spreads are wide, and moves that look dramatic in premarket trading frequently compress, reverse, or accelerate once institutional order flow enters the market. Chasing stocks that have already surged 35–96% before the open is one of the highest-risk strategies in trading.

Specific risks by name: CAPR's biotech catalyst is the most substantive, but binary FDA events can disappoint even when the setup looks compelling. CYCU faces a Nasdaq delisting hearing in six days. AKAN has no confirmed catalyst. STKH has no confirmed catalyst and a bearish prior-day candlestick. SXTC has a recent dilutive offering on file. Patterns and squeeze setups fail regularly — always define your risk before entering any position.

After every close and every premarket session, StockSetups scans the full US universe of roughly 12,300 stocks, detects confirmed chart patterns, and scores each setup for conviction, squeeze potential, and smart-money activity — so you can see which of the morning's movers have real technical backing and which are pure momentum plays. Check yesterday's after-close recap to see how the prior session's biggest gainers set up heading into today.

This article is for educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always do your own research and manage your risk.